Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02724956 · ClinicalTrials.gov registry record · NA
Ambu AuraGain and Teleflex LMA Protector Fiberoptic Assessments in Elective Patients
A NA study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 53
- Enrollment target
NCT02724956: Completed NA study, sponsored by M.D. Anderson Cancer Center.
NCT02724956 is a NA study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 53 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02724956, a NA study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 53 participants
- Enrollment target
Study Summary
Participant is being asked to take part in this study because participant is going to have surgery that requires general anesthesia (in which participant is unconscious for the procedure). During surgery, anesthesiologists often place a supraglottic airway device (SGAD). An SGAD is a device that helps participant breathe and may help the anesthesiologist put a breathing tube in participant's airway while participant is asleep during surgery. There are many different kinds of SGADs that are readily available for use by anesthesiologists during surgery. The SGADs that are being studied are the Ambu Auragain and the Teleflex LMA Protector. The goal of this clinical research study is to compare the effectiveness of both devices. This is an investigational study. Both of the SGADs that are being used on this study are FDA approved and are frequently used for the surgery that participant is going to have. It is investigational to compare the 2 devices. Up to 50 participants will be enrolled in this study. All will take part at MD Anderson.
Interventions
- DEVICE Ambu AuraGain
- DEVICE Teleflex LMA Protector
- DEVICE Ambu aScope
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2017-11-29 |
| Est. Completion | 2020-12-18 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02724956
The ClinicalTrials.gov registry entry for NCT02724956 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ambu AuraGain is the first listed.
NCT02724956 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02724956 about?
NCT02724956 is a clinical study titled "Ambu AuraGain and Teleflex LMA Protector Fiberoptic Assessments in Elective Patients". Participant is being asked to take part in this study because participant is going to have surgery that requires general anesthesia (in which participant is unconscious for the procedure). During surgery, anesthesiologists often place a supraglottic airway device (SGAD). An SGAD is a device that he...
What is the current status of trial NCT02724956?
This trial is currently completed. It is a NA study. The enrollment target is 53 participants. The study started on 2017-11-29. Estimated completion is 2020-12-18.
What interventions are being tested in trial NCT02724956?
The interventions under investigation include: Ambu AuraGain (DEVICE), Teleflex LMA Protector (DEVICE), Ambu aScope (DEVICE).
Who is sponsoring clinical trial NCT02724956?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.